Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 20 August 2012 | By Ansis Helmanis,
Australia's Therapeutic Goods Administration (TGA) has concluded that over-the-counter (OTC) cough and cold medicines registered with the agency should not be given to children under the age of six, and should be given only on the advice of health professionals for those ages six to 12.
The restrictions stem from a review of the safety and efficacy of these products conducted by the agency that found although there are no immediate safety risks associated with the products, there are potential risks for children with only limited evidence of benefits.
Products placed on the market prior to 1 September 2012, will be allowed to remain on the market, but products marketed after that date must include the revised labeling.
Read more:
Read all Breaking News from RegLink
Tags: Codeine, OTC, Children, Pediatric, review
Regulatory Focus newsletters
All the biggest regulatory news and happenings.